Shares in 23andMe are currently trading at around $3.40, giving it a valuation of just under $82 million. The company went ...

Me is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing ...

The testing company ended last year with $79 million and told investors it will need to raise money to fund its operations ...

Me (ME), the company that popularized consumer genetic testing, announced Tuesday that it is once again exploring “strategic ...

By the 2023 fiscal year, 23andMe had reported a net loss of $312 million and its individual share price has plummeted a ...

At-home DNA testing is no longer in high demand — and critics have raised concerns about unreliable tests and privacy.

Me (ME) forms special board committee to explore strategic alternatives, including sale, restructuring, or business ...

23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter ...

The DNA-testing company is exploring its options, including a business combination and the sale of some or all of its assets.

23andMe is considering a sale of the company as it weighs up strategic options, capping a torrid year for the genetic testing business. A special committee of its directors’ board is considering ...